Riverview Patients Join National Lawsuits Against GLP-1 Drugmakers Over Vision Loss Claims

Riverview residents who use popular GLP-1 medications like Ozempic, Wegovy, and Mounjaro may be impacted by a growing wave of personal injury lawsuits filed against the drug manufacturers. These lawsuits allege that the companies failed to adequately warn patients about a potential side effect: nonarteritic anterior ischemic optic neuropathy (NAION), a condition leading to sudden vision loss.

Almost 1,000 lawsuits related to GLP-1 drugs and vision loss have been filed in New Jersey alone over the past year. These legal challenges claim that manufacturers did not include NAION warnings on their U.S. product labels, despite some of these drugs carrying such warnings in other countries. The legal actions highlight a significant concern for patient safety and the transparency of pharmaceutical warnings.

NAION occurs when there is insufficient blood flow to the optic nerve, which can result in sudden, painless vision loss. This condition typically affects one eye first, though about 15% of individuals may eventually experience it in the second eye. The American Academy of Ophthalmology states there is currently no proven treatment for NAION, a rare condition that usually affects people over 50.

A medical facility in Boston issued a safety alert in 2024 regarding a possible connection between GLP-1 drugs and NAION. While no study has definitively proven the drugs caused NAION, the lawsuits contend that patients deserved to be informed of this potential risk. Both Novo Nordisk and Lilly, manufacturers of the implicated drugs, deny the allegations. Novo Nordisk stated they take all reports of adverse events seriously but consider the lawsuits without merit and are vigorously defending them. Lilly also affirmed patient safety as a top priority, noting they actively monitor, evaluate, and report safety information to the FDA.

As these lawsuits proceed, the medical community continues to monitor and research the potential links between GLP-1 medications and NAION. Patients currently using these drugs should consult their healthcare providers with any concerns regarding their vision or potential side effects.